Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
EVH

EVH - Evolent Health Inc Stock Price, Fair Value and News

19.67USD-0.46 (-2.29%)Market Closed

Market Summary

EVH
USD19.67-0.46
Market Closed
-2.29%

EVH Stock Price

View Fullscreen

EVH RSI Chart

EVH Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-20.72

Price/Sales (Trailing)

1.05

EV/EBITDA

67.96

Price/Free Cashflow

14.7

EVH Price/Sales (Trailing)

EVH Profitability

Operating Margin

20.56%

EBT Margin

-6.02%

Return on Equity

-10.53%

Return on Assets

-4.17%

Free Cashflow Yield

6.8%

EVH Fundamentals

EVH Revenue

Revenue (TTM)

2.2B

Rev. Growth (Yr)

49.56%

Rev. Growth (Qtr)

15.03%

EVH Earnings

Earnings (TTM)

-110.3M

Earnings Growth (Yr)

13.52%

Earnings Growth (Qtr)

48.28%

Breaking Down EVH Revenue

Last 7 days

2.7%

Last 30 days

-8.7%

Last 90 days

-31.7%

Trailing 12 Months

-35.9%

How does EVH drawdown profile look like?

EVH Financial Health

Current Ratio

1.02

Debt/Equity

0.57

Debt/Cashflow

0.26

EVH Investor Care

Shares Dilution (1Y)

3.15%

Diluted EPS (TTM)

-1.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.2B000
20231.5B1.6B1.8B2.0B
2022989.9M1.1B1.2B1.4B
2021918.5M923.2M906.1M908.0M
2020869.9M895.2M914.6M924.6M
2019685.1M732.8M803.0M846.4M
2018468.4M505.7M547.7M627.1M
2017311.0M361.5M409.2M434.9M
2016146.3M192.4M212.2M254.2M
2015049.4M73.1M96.9M
201300025.7M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Evolent Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 06, 2024
keck kim
acquired
-
-
7,709
-
Jun 06, 2024
barbarosh craig a.
acquired
-
-
7,709
-
Jun 06, 2024
duffy mary bridget
acquired
-
-
7,709
-
Jun 06, 2024
scott cheryl
acquired
-
-
7,709
-
Jun 06, 2024
grua peter j
acquired
-
-
7,709
-
Jun 06, 2024
glass russell monroe
acquired
-
-
7,709
-
Jun 06, 2024
holder diane
acquired
-
-
7,709
-
Jun 06, 2024
ajayi toyin
acquired
-
-
7,709
-
Jun 06, 2024
jelinek richard m
acquired
-
-
7,709
-
Mar 02, 2024
mccarthy daniel joseph
sold (taxes)
-194,004
34.41
-5,638
president

1–10 of 50

Which funds bought or sold EVH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 18, 2024
Blue Trust, Inc.
new
-
1,115
1,115
-%
Jul 18, 2024
VALLEY NATIONAL ADVISERS INC
sold off
-100
-3,000
-
-%
Jul 18, 2024
ERn Financial, LLC
added
100
324,679
2,278,110
0.19%
Jul 18, 2024
Genesee Capital Advisors, LLC
sold off
-100
-1,193,360
-
-%
Jul 17, 2024
KBC Group NV
added
30.07
-19,000
57,000
-%
Jul 16, 2024
SJS Investment Consulting Inc.
unchanged
-
-27.00
39.00
-%
Jul 15, 2024
JFS WEALTH ADVISORS, LLC
new
-
306
306
-%
Jul 12, 2024
SG Americas Securities, LLC
sold off
-100
-263,000
-
-%
Jul 12, 2024
Sonora Investment Management Group, LLC
unchanged
-
-
6,056,700
0.47%
Jul 12, 2024
WOLFF WIESE MAGANA LLC
unchanged
-
-41,010
57,360
0.05%

1–10 of 43

Are Funds Buying or Selling EVH?

Are funds buying EVH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EVH
No. of Funds

Unveiling Evolent Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 10, 2024
fmr llc
-
0
SC 13G/A
Jun 17, 2024
ra capital management, l.p.
7.1%
8,279,103
SC 13G
Apr 09, 2024
jpmorgan chase & co
4.0%
4,679,353
SC 13G/A
Feb 13, 2024
vanguard group inc
9.41%
10,821,331
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
7.23%
8,313,157
SC 13G
Jan 26, 2024
blackrock inc.
7.3%
8,423,999
SC 13G/A
Jan 18, 2024
jpmorgan chase & co
5.1%
5,863,530
SC 13G/A
Apr 26, 2023
magellan health inc
0%
0
SC 13G/A
Apr 10, 2023
fmr llc
-
0
SC 13G

Recent SEC filings of Evolent Health Inc

View All Filings
Date Filed Form Type Document
Jul 10, 2024
SC 13G/A
Major Ownership Report
Jun 17, 2024
SC 13G
Major Ownership Report
Jun 11, 2024
8-K
Current Report
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading

Peers (Alternatives to Evolent Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
520.4B
379.5B
17.33% 12.05%
33.88
1.37
12.96% -25.81%
95.4B
206.0B
1.72% 16.37%
24.76
0.46
12.55% -43.95%
84.3B
66.7B
-5.62% 12.14%
15.42
1.26
9.59% -4.59%
74.8B
360.9B
-1.82% -19.47%
10.21
0.21
9.07% 78.83%
35.4B
155.5B
-1.07% -4.10%
12.93
0.23
6.34% 84.42%
12.2B
14.7B
-4.81% 19.04%
14.88
0.83
7.99% 19.23%
12.1B
12.3B
-4.32% 29.88%
14.83
0.98
5.77% 58.74%
MID-CAP
8.2B
2.3B
1.82% -0.86%
28.98
3.58
5.96% 18.29%
6.2B
3.0B
-2.69% -11.33%
-545.53
2.06
10.92% -104.06%
2.8B
1.5B
17.05% 40.55%
44.28
1.9
19.34% 40.15%
2.2B
3.5B
6.32% -49.56%
15.06
0.62
-27.67% -62.40%
SMALL-CAP
1.9B
1.1B
0.03% 29.58%
29.63
1.79
11.45% 30.74%
1.5B
3.0B
16.04% 110.14%
-8.5
0.49
4.98% 4.88%
72.1M
-
21.59% -10.97%
-4.77
-
- -1.05%
20.6M
21.6M
-0.62% 19.10%
40.5
0.95
9.04% -57.88%

Evolent Health Inc News

Latest updates
MarketBeat4 hours ago
MarketBeat16 Jul 202410:31 pm

Evolent Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue15.0%639,653,000556,055,000511,015,000469,136,000427,690,000382,432,000352,585,000319,939,000297,057,000248,358,000222,471,000222,057,000215,071,000246,536,000239,572,000217,299,000221,232,000236,525,000220,143,000191,959,000197,756,000
Cost Of Revenue17.9%535,547,000454,428,000386,585,000351,938,000310,475,000299,368,000266,617,000249,705,000219,739,000------------
Costs and Expenses13.1%653,062,000577,405,000528,953,000490,704,000438,045,000384,310,000339,634,000324,572,000299,855,000260,572,000229,052,000229,728,000---------
Operating Expenses---------299,855,000260,572,000229,052,000229,728,000231,016,000246,804,000256,020,000443,128,000246,323,000451,120,000240,281,000217,192,000244,402,000
  S&GA Expenses-2.9%79,104,00081,428,00096,567,00090,389,00089,726,00082,861,00068,521,00058,955,00058,932,00066,917,00051,292,00042,699,00058,591,00058,663,00052,366,00047,296,00052,087,00035,870,00058,808,00066,932,00074,838,000
EBITDA Margin245.7%0.02-0.010.00-0.02-0.030.020.020.050.060.060.050.02---------
Interest Expenses-51.0%5,997,00012,238,00014,614,00014,458,00012,895,0006,429,0004,754,0002,148,0002,241,0006,447,0006,367,0006,274,0006,337,0008,338,0007,416,0006,290,0006,281,0003,743,0003,630,0003,620,0003,562,000
Income Taxes-97.0%565,00018,604,500-5,550,000-970,000-68,189,0001,115,000-45,500,000-184,0001,202,000-453,000234,00091,000611,000763,000503,000-3,904,000270,000-22,848,000-849,0001,398,000-496,000
Earnings Before Taxes65.2%-16,715,000-48,067,000-30,874,000-35,293,000-88,171,000-10,227,000-43,393,000-4,309,000-4,148,0002,600,000-12,806,000-9,016,000-10,579,000-9,874,000-36,532,000-205,917,000-78,217,000-223,754,000-26,587,000-30,502,000-49,145,000
EBT Margin41.6%-0.06-0.10-0.09-0.11-0.10-0.05-0.04-0.02-0.02-0.03-0.05-0.07---------
Net Income48.3%-17,280,000-33,411,000-25,324,000-34,323,000-19,982,000-11,349,0002,123,000-4,588,000-5,350,000-5,647,000-13,040,000-9,107,000-9,807,000822,000-822,000---198,096,000-25,521,000-31,615,000-46,739,000
Net Income Margin11.9%-0.05-0.06-0.05-0.04-0.02-0.01-0.01-0.03-0.03-0.04-0.03-0.02---------
Free Cashflow-94.5%4,909,00089,381,00051,364,000-8,503,000-17,131,00026,538,000-12,627,0004,507,000-66,599,00057,499,00035,344,000-33,404,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.4%2,6442,6802,6702,6472,5891,8171,7591,3041,3391,4191,2541,2931,3061,3721,3921,2701,4511,4981,7141,6521,629
  Current Assets-2.1%669684639577476478394423463524478506508548549275258229308241321
    Cash Equivalents-14.4%16519318514315821515719321035528223830436237198.0068.0012997.0093.00171
  Net PPE-2.7%76.0078.0080.0084.0089.0088.0095.0093.0083.0081.0082.0083.0084.0086.0088.0089.0086.0085.0083.0080.0077.00
  Goodwill0.0%1,1171,1171,1181,1181,11872372342642642677.00349349349349349570566772772770
Liabilities-1.4%1,4141,4341,3981,3811,297958903691728726646679688752737623604569590506479
  Current Liabilities-2.3%659674615541458433382343382445367403415403365245236193260173164
  Short Term Borrowings---1.00------------------
  Long Term Debt0.1%598597600633632413412283283216211207202263285300297294228226223
    LT Debt, Current-----------27.0027.0027.0027.00-------
    LT Debt, Non Current0.1%598597600633632413412283283216211207202263---294---
Shareholder's Equity-1.9%1,0481,0681,0961,0931,1228598566136116946076146176206556478479291,1241,1471,150
  Retained Earnings-2.4%-736-719-685-660-626-606-594-596-592-626-621-608-598-589-574-537-333-251-53.87-28.343.00
  Additional Paid-In Capital-0.1%1,8061,8081,8031,7751,7691,4871,4721,2311,2241,3411,2491,2431,2371,2291,2251,1841,1801,1741,1621,1581,096
Shares Outstanding2.6%11411111211110894.0095.0090.0090.0086.0086.0085.00---------
Minority Interest---------------25.00--7.0016.0016.0050.00
Float----3,400---2,500---1,600---540---600-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-94.5%4,90989,38160,521654-7,97435,695-3,47013,664-57,44266,65644,501-24,247-48,163-12,851-20,49937,666-20,54113,187-16,590-13,533-25,709
  Share Based Compensation77.2%18,78610,60310,2228,96610,71014,6316,9927,0125,3464,9574,3953,6533,7064,2313,1643,7033,5085735,7584,7504,537
Cashflow From Investing-60.8%-9,732-6,052-6,145-8,354-394,993-4,456-254,989-16,43616,766-54,368-1,798-5,57145,951-2,225281,679-7,575-10,807-79,174-11,644-65,338-25,478
Cashflow From Financing117.6%14,882-84,352-37,36723,330379,729-10,854173,08120,690-51,37660,898641-35,503-55,584-23,916-13,856-6,66432,574-11,24696,772-11,406-109,665
  Buy Backs----------------685-----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EVH Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue[1]$ 639,653$ 427,690
Expenses  
Cost of revenue[1]535,547310,475
Selling, general and administrative expenses[1]79,10489,726
Depreciation and amortization expenses29,50329,275
Change in fair value of contingent consideration8,9088,569
Total operating expenses653,062438,045
Operating loss(13,409)(10,355)
Interest income2,5501,060
Interest expense(5,997)(12,895)
Gain from equity method investees306423
Change in tax receivables agreement liability(173)(66,184)
Other income (expense), net8(220)
Loss before income taxes(16,715)(88,171)
Provision for (benefit from) income taxes565(68,189)
Loss before preferred dividends and accretion of Series A Preferred Stock(17,280)(19,982)
Dividends and accretion of Series A Preferred Stock(7,945)(6,276)
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic(25,225)(26,258)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted$ (25,225)$ (26,258)
Basic and diluted  
Basic (in dollars per share)$ (0.22)$ (0.24)
Diluted (in dollars per share)$ (0.22)$ (0.24)
Weighted-average common shares outstanding  
Basic (in shares)114,141107,783
Diluted (in shares)114,141107,783
Comprehensive loss  
Net loss attributable to common shareholders of Evolent Health, Inc.$ (25,225)$ (26,258)
Other comprehensive loss, net of taxes, related to:  
Foreign currency translation adjustment(51)56
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.$ (25,276)$ (26,202)
[1]See Note 18 for amounts attributable to unconsolidated related parties included in these line items.

EVH Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 165,147$ 192,825
Restricted cash and restricted investments51,59413,768
Accounts receivable, net[1]427,739446,749
Prepaid expenses and other current assets24,76630,331
Total current assets669,246683,673
Restricted cash and restricted investments16,73716,864
Investments and equity method investees8,1974,895
Property and equipment, net76,04478,194
Right-of-use assets - operating10,79011,983
Prepaid expenses and other noncurrent assets2,3044,028
Contract cost assets12,47112,120
Intangible assets, net731,345752,009
Goodwill1,116,5391,116,542
Total assets2,643,6732,680,308
Current liabilities:  
Accounts payable[1]77,34648,246
Accrued liabilities[1]165,099149,849
Operating lease liability - current12,6969,738
Accrued compensation and employee benefits29,10656,385
Deferred revenue6,1365,976
Reserve for claims and performance - based arrangements368,639404,048
Total current liabilities659,022674,242
Long-term debt, net597,901597,049
Other long-term liabilities3,5683,637
Tax receivables agreement liability108,105107,932
Operating lease liabilities - noncurrent32,46938,009
Deferred tax liabilities, net13,37813,311
Total liabilities1,414,4431,434,180
Commitments and Contingencies (See Note 10)
Mezzanine Equity  
Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 175,000 issued, respectively181,294178,427
Shareholders' Equity  
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 116,195,270 and 115,424,833 shares issued, respectively1,1621,154
Additional paid-in-capital1,805,6791,808,121
Accumulated other comprehensive loss(1,308)(1,257)
Retained earnings (accumulated deficit)(736,474)(719,194)
Treasury stock, at cost; 1,537,582 shares issued, respectively(21,123)(21,123)
Total shareholders' equity1,047,9361,067,701
Total liabilities, mezzanine equity and shareholders' equity$ 2,643,673$ 2,680,308
Preferred class A common stock, shares issued (in shares)175,000175,000
[1]See Note 18 for amounts attributable to related parties included in these line items.
EVH
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology, cardiology, and musculoskeletal markets; physician-oriented total cost of care solutions; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
 CEO
 WEBSITEevolenthealth.com
 INDUSTRYHealthcare Plans
 EMPLOYEES5100

Evolent Health Inc Frequently Asked Questions


What is the ticker symbol for Evolent Health Inc? What does EVH stand for in stocks?

EVH is the stock ticker symbol of Evolent Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Evolent Health Inc (EVH)?

As of Thu Jul 18 2024, market cap of Evolent Health Inc is 2.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EVH stock?

You can check EVH's fair value in chart for subscribers.

What is the fair value of EVH stock?

You can check EVH's fair value in chart for subscribers. The fair value of Evolent Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Evolent Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EVH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Evolent Health Inc a good stock to buy?

The fair value guage provides a quick view whether EVH is over valued or under valued. Whether Evolent Health Inc is cheap or expensive depends on the assumptions which impact Evolent Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EVH.

What is Evolent Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, EVH's PE ratio (Price to Earnings) is -21.2 and Price to Sales (PS) ratio is 1.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EVH PE ratio will change depending on the future growth rate expectations of investors.